Literature DB >> 3143478

Cost-effectiveness of primary tetanus vaccination among elderly Canadians.

B G Hutchison1, G L Stoddart.   

Abstract

Although tetanus is now rare, vaccination is currently recommended for the entire population. Most elderly North Americans have never received tetanus vaccination. We evaluated the expected cost-effectiveness of using mailed reminders from family physicians to increase primary tetanus vaccination coverage among elderly Canadians. We estimated that over 10 years the program would prevent five cases of tetanus and one death from tetanus, resulting in a gain of 13 life-years. There would be 16,700 adverse reactions to tetanus toxoid, 17% in people already immune to tetanus. The net cost of the program (in 1984 Canadian dollars) would be $1.9 million per case of tetanus prevented, $7.1 million per death prevented and $810,000 per life-year gained. These high cost-effectiveness ratios are largely attributable to the very low risk of tetanus, even among nonimmune elderly people. Tetanus toxoid and physicians' services for vaccination would account for 86% of the program costs. Because the mailed reminders would be responsible for only 13% of the program costs, other possible programs to increase primary tetanus vaccination coverage could not be expected to have substantially lower cost-effectiveness ratios. We conclude that efforts to increase primary tetanus vaccination coverage among elderly Canadians would be a questionable use of health care resources.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143478      PMCID: PMC1268477     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  29 in total

1.  Influenza and pneumococcal immunization strategies for physicians.

Authors:  D S Fedson
Journal:  Chest       Date:  1987-03       Impact factor: 9.410

2.  The use of toxoid for the prevention of tetanus neonatorum. Final report of a double-blind controlled field trial.

Authors:  K W Newell; A Dueñas Lehmann; D R LeBlanc; N Garces Osorio
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

3.  The swine-influenza decision.

Authors:  S C Schoenbaum; B J McNeil; J Kavet
Journal:  N Engl J Med       Date:  1976-09-30       Impact factor: 91.245

4.  Tetanus toxoid: what determines reaction proneness?

Authors:  L Levine; G Edsall
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

5.  A serologic survey of tetanus and diphtheria immunity in New York City.

Authors:  S J Millian; C E Cherubin; R Sherwin; H T Fuerst
Journal:  Arch Environ Health       Date:  1967-12

6.  Duration of immunity to diphtheria and tetanus after active immunization.

Authors:  I Scheibel; M W Bentzon; P E Christensen; A Biering
Journal:  Acta Pathol Microbiol Scand       Date:  1966

7.  Reactions to tetanus toxoid.

Authors:  W G White; G M Barnes; E Barker; D Gall; P Knight; A H Griffith; R M Morris-Owen; J W Smith
Journal:  J Hyg (Lond)       Date:  1973-06

8.  Do postcard reminders improve influenza compliance? A prospective trial of different postcard "cues".

Authors:  E B Larson; J Bergman; F Heidrich; B L Alvin; R Schneeweiss
Journal:  Med Care       Date:  1982-06       Impact factor: 2.983

9.  Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines.

Authors:  L H Collier; S Polakoff; J Mortimer
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

10.  Influenza vaccination.

Authors:  M A Riddiough; J E Sisk; J C Bell
Journal:  JAMA       Date:  1983-06-17       Impact factor: 56.272

View more
  10 in total

Review 1.  Pharmacoeconomics of immunisation: a review.

Authors:  R van den Oever; D de Graeve; B Hepp; A Stroobant; D Walckiers; V Van Casteren; F Van Loock; G Ducoffre; J Dewatripont; P Jacques
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

Review 2.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

3.  Indices of therapeutic outcome in pharmacoeconomic evaluation of drug therapy.

Authors:  S F Hurley
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

4.  Current principles and application of pharmacoeconomics.

Authors:  M Malek
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

5.  Prevention and early detection in family medicine: where are we?

Authors:  J W Feightner
Journal:  Can Fam Physician       Date:  1989-09       Impact factor: 3.275

6.  Cost-effectiveness of primary tetanus vaccination among elderly Canadians.

Authors:  T J Muckle
Journal:  CMAJ       Date:  1989-03-15       Impact factor: 8.262

7.  Tetanus immunization: concerns about the elderly and about diphtheria reemergence.

Authors:  J P Richardson
Journal:  J Gen Intern Med       Date:  1994-02       Impact factor: 5.128

8.  Epidemiology of tetanus in the Marches Region of Italy, 1992-95.

Authors:  E Prospero; R Appignanesi; M M D'Errico; F Carle
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

9.  Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis.

Authors:  D J Balestra; B Littenberg
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

Review 10.  Economic evaluations of vaccines in Canada: a scoping review.

Authors:  Ellen R S Rafferty; Heather L Gagnon; Marwa Farag; Cheryl L Waldner
Journal:  Cost Eff Resour Alloc       Date:  2017-05-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.